NovoCure Limited
NVCR
$17.24
$0.392.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.30% | 8.11% | 7.81% | 5.62% | 11.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.30% | 8.11% | 7.81% | 5.62% | 11.91% |
| Cost of Revenue | 1.06% | 24.61% | 26.45% | 19.67% | 14.34% |
| Gross Profit | 16.01% | 3.96% | 2.30% | 1.41% | 11.12% |
| SG&A Expenses | 46.76% | -20.28% | 4.54% | 7.10% | 3.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.72% | -4.55% | 8.57% | 7.82% | 5.85% |
| Operating Income | -89.57% | 38.38% | -12.24% | -17.69% | 14.34% |
| Income Before Tax | -128.61% | 25.82% | -39.09% | -53.90% | 4.26% |
| Income Tax Expenses | -53.28% | -253.56% | -19.33% | -51.53% | -43.47% |
| Earnings from Continuing Operations | -107.28% | 62.84% | -21.92% | -20.27% | 11.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.28% | 62.84% | -21.92% | -20.27% | 11.46% |
| EBIT | -89.57% | 38.38% | -12.24% | -17.69% | 14.34% |
| EBITDA | -96.33% | 41.17% | -9.19% | -17.43% | 16.70% |
| EPS Basic | -100.26% | 64.08% | -17.92% | -16.10% | 13.87% |
| Normalized Basic EPS | -138.94% | 22.42% | -34.59% | -41.44% | 13.94% |
| EPS Diluted | -100.26% | 64.08% | -17.92% | -16.10% | 13.87% |
| Normalized Diluted EPS | -138.94% | 22.42% | -34.59% | -41.44% | 13.94% |
| Average Basic Shares Outstanding | 3.51% | 3.47% | 3.38% | 3.60% | 2.81% |
| Average Diluted Shares Outstanding | 3.51% | 3.47% | 3.38% | 3.60% | 2.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |